AIM IP specialist Tekcapital to sell or float all four portfolio companies 'within 2 years'. Watch the full video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,330.20
Bid: 1,330.20
Ask: 1,330.80
Change: -21.60 (-1.60%)
Spread: 0.60 (0.05%)
Open: 1,344.00
High: 1,347.40
Low: 1,319.60
Yest. Close: 1,351.80
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Glaxo's ViiV Gets Vocabria Boost From European Regulator

Fri, 16th Oct 2020 12:41

(Alliance News) - GlaxoSmithKline PLC on Friday said its majority-owned ViiV Healthcare unit received a "positive opinion" from a European health watchdog for its Vocabria HIV treatment.

The Committee for Medicinal Products for Human Use, part of the European Medicines Agency, recommended marketing authorisation for the medication to treat HIV-1 in adults.

ViiV Chief Executive Officer Deborah Waterhouse said: "Today's positive CHMP opinion marks an important step in providing a new option that changes the treatment experience for people living with HIV across Europe."

Data showed Vocabria, when used in tandem with Johnson & Johnson's Rekambys injection, reduces treatment dosing days from every day of the year to just 12 or 6 per year.

"Vocabria injection used in combination with Rekambys has the potential to ease the day-to-day burden of HIV by offering significantly less frequent dosing from 365 days with oral regimens to 12 or 6 treatments per year. Through our innovative R&D, we are now one step closer to offering an HIV medicine in Europe with a novel route of administration and dosing schedule compared to other therapies. We're proud to be providing different treatment options that meet the diverse needs of the HIV community," Waterhouse added.

ViiV is majority owned by Glaxo and has Pfizer Inc among its shareholders.

GSK's stock was up 2.7% at 1,413.60 pence each in London on Friday afternoon.

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News

Tuesday broker round-up

(Sharecast News) - Safestore: Liberum upgrades to buy with a target price of 1,060p.

Today 13:31

BROKER RATINGS: Vodafone on Goldman Sachs' Conviction Buy List

BROKER RATINGS: Vodafone on Goldman Sachs' Conviction Buy List

Today 09:43

CORRECTED-Forestry firm Stora Enso to supply Diageo pulp for paper whisky bottles

(Corrects description of material used in bottle lining in 5th paragraph)By Essi LehtoHELSINKI, May 11 (Reuters) - Finnish forestry firm Stora Enso said on Tuesday it would start supplying pulp for sustainable packaging company Pulpex, a research ...

Today 07:14

IN BRIEF: EMA starts rolling review of Covid treatment by GSK and Vir

IN BRIEF: EMA starts rolling review of Covid treatment by GSK and Vir

7 May 21 14:08

CureVac says well on track to request vaccine approval as planned

* Says infections rate within trial population is high* Some doses aimed for production in '21 to be delivered in '22* Trial result will also offer unique view on spread of variantsBy Ludwig BurgerFRANKFURT, May 5 (Reuters) - Germany's CureVac is ...

5 May 21 15:54

UK prosecutor ends investigation into Airbus individuals - sources

By Kirstin RidleyLONDON, May 4 (Reuters) - Britain's Serious Fraud Office (SFO) has ended a criminal investigation into individuals associated with Airbus, the European planemaker that agreed to a record $4.0 billion global settlement 16 months ag...

4 May 21 16:34

GSK's ViiV says HIV drug gets rolling probe from US watchdog

GSK's ViiV says HIV drug gets rolling probe from US watchdog

4 May 21 14:29

Sunday newspaper round-up: GlaxoSmithKline, Rare Earths, Amazon

(Sharecast News) - Top investors in Glaxo Smith Kline are piling pressure on Dame Emma Walmsley after the activist New York hedge fund Elliott Management was revealed to have built a significant stake. Two top-20 investors in the drugs and consumer goods giant said that the chief executive's future was in doubt after four years of disappointing performance. One top-20 investor said there was "no desire to protect her" among institutional shareholders. Another said that Walmsley, 51, should step aside after her plan to break the business in two is carried out and hand over to her lieutenant, Luke Miels. - Sunday Times

2 May 21 12:32

LONDON MARKET MIDDAY: Eurozone recession and Barclays slide quash gain

LONDON MARKET MIDDAY: Eurozone recession and Barclays slide quash gain

30 Apr 21 12:13

BROKER RATINGS: Johnson Matthey and Meggitt receive upgrades

BROKER RATINGS: Johnson Matthey and Meggitt receive upgrades

30 Apr 21 09:43

LONDON MARKET CLOSE: Stocks subdued ahead of US Fed rate decision

LONDON MARKET CLOSE: Stocks subdued ahead of US Fed rate decision

28 Apr 21 17:01

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

28 Apr 21 16:06

TOP NEWS: GSK reports first quarter revenue drop amid Covid-19 impact

TOP NEWS: GSK reports first quarter revenue drop amid Covid-19 impact

28 Apr 21 12:40

GSK sticks to guidance after crisis hits profit and revenue

(Sharecast News) - GlaxoSmithKline stuck to its annual guidance after the Covid-19 crisis caused profit and revenue to fall in the first quarter of 2021.

28 Apr 21 12:23

UPDATE 1-GSK exceeds earnings expectations despite sales falling short

(Adds details on earnings, outlook)April 28 (Reuters) - GSK topped analysts' expectations for first-quarter earnings as more people visited clinics for critical treatments such as HIV and routine shots once COVID-19 curbs eased, adding on Wednesda...

28 Apr 21 12:20

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.